SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2018
Commission File Number: 001-38205
ZAI LAB LIMITED
(Translation of registrants name into English)
4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Appointment of Chief Financial Officer
On March 5, 2018, Zai Lab Limited (the Company) issued a press release announcing the appointment of Billy Cho as Chief Financial Officer. The press release is attached as Exhibit 99.1 and is incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized..
ZAI LAB LIMITED
| ||
By: | /s/ Samantha Du | |
Name: Samantha Du | ||
Title: Chief Executive Officer |
Dated: March 5, 2018
EXHIBIT INDEX
Exhibit No. |
Description | |
Exhibit 99.1 | Press release issued March 5, 2018 |
Exhibit 99.1
Zai Lab Limited Appoints Billy Cho as Chief Financial Officer
SHANGHAI, China. March 5, 2018: Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the appointment of Billy Cho as Chief Financial Officer. Mr. Cho joins from Citigroup where he was the Managing Director and Head of Asia Healthcare Investment Banking.
We are very excited to welcome Billy as part of the Zai Lab team and as our Chief Financial Officer, said Samantha Du, Chairman and Chief Executive Officer at Zai Lab. I have known Billy for many years and his extensive background in the sector globally, along with his proven capabilities in leadership, finance and strategic thinking, will greatly strengthen and complement our management team and allow us to continue advancing Zai Lab into a fully-integrated, global biopharmaceutical company.
Mr. Cho has nearly 18 years of experience in the healthcare industry across the US and Asia. Based in Hong Kong for the past seven years, Mr. Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important healthcare transactions in China including Zai Labs US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Mr. Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies.
I strongly believe this is the time to join Samantha and Zai Labs talented leadership team to help bring transformative medicines to China and globally, said Billy Cho. The Company is advancing its late-stage pipeline with drugs that are expected to dramatically improve treatment options for cancer, autoimmune and infectious diseases. I look forward to complementing the already exceptional team Samantha has helped build at Zai Lab as we continue to execute on its vision of bringing innovative therapies to China and beyond.
Mr. Cho earned his MBA from the Wharton School of the University of Pennsylvania.
About Zai Lab
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The companys experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of Chinas pharmaceutical market and global unmet medical needs. Zai Labs vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners and its own products in order to impact human health worldwide.
******
Contact:
Zai Lab
Jonathan Wang
+86 21 6163 2588
jwang@zailaboratory.com
The Trout Group
John Graziano
+1 646 378 2942
jgraziano@troutgroup.com